-

SpineX Demonstrates Ground Breaking Technology to Improve Bladder Function in Stroke Survivors

LOS ANGELES--(BUSINESS WIRE)--SpineX Inc., a clinical stage bioelectric medtech company, has had an important publication accepted in the prestigious Journal of Urology. The publication, entitled A Pilot Study of the Effect of Transcutaneous Spinal Cord Stimulation on Micturition-Related Brain Activity and Lower Urinary Tract Symptoms after Stroke shows improved bladder function and restoration of brain activity associated with normal voiding in stroke survivors who completed SpineX SCONE™ therapy.

“This is a significant advancement in our research,” says Dr. Evgeniy Kreydin, SpineX’s co-founder and Chief Medical Officer, and an adjunct assistant professor of clinical urology at the University of Southern California. “We are able to show clinical evidence that our technology can make a difference in the lives of stroke patients.”

Improved bladder function is a high priority for stroke survivors, affording the ability to sleep longer periods of time, drive longer distances and live fuller lives - all important advances that align with SpineX’s key mission to improve the lives of people living with neurological conditions. The publication demonstrates that SCONE therapy corrects brain activity changes after stroke, bringing post-stroke brain activity associated with bladder control to a level similar to that of healthy individuals. This improved brain function is directly associated with clinically significant improvement in bladder function.

“We’re moving forward rapidly with this technology,” confirms Kreydin. “Right now we’re recruiting for a clinical trial with our SCONE device in numerous locations in North America, and India.” Individuals interested in the trial should visit: https://spinex.co/join-us/clinical-trials/.

About SpineX Inc.

SpineX Inc., a clinical stage bioelectric MedTech company developing noninvasive spinal cord neuromodulation devices as a platform technology. SCONE™ and SCiP™ are two FDA-designated Breakthrough Devices being developed by SpineX for the treatment of adults with Neurogenic Bladder and Children with Cerebral Palsy respectively. To learn more about SpineX, visit http://www.spinex.co or follow @spinex_inc on social media.

Contacts

Jennifer Boon, Head of Communications, SpineX
media@spinex.co

SpineX Inc.


Release Versions

Contacts

Jennifer Boon, Head of Communications, SpineX
media@spinex.co

More News From SpineX Inc.

SpineX Inc. Announces Significant Improvement in Urinary Bladder Function in Paralyzed Individuals with SCONE™ Therapy

LOS ANGELES--(BUSINESS WIRE)--SpineX Inc., a pioneering medical technology company developing innovative non-surgical spinal cord neuromodulation solutions, today announced the results of its global, multisite pivotal trial, CONTINENCE, evaluating the safety and efficacy of SCONE™ therapy for neurogenic bladder (NB) in individuals with paralysis due to spinal cord injury (SCI), stroke, or multiple sclerosis (MS). The study demonstrated a statistically significant improvement in NB symptoms in t...

SpineX Closes Recruitment for SCONE™ Clinical Trial

LOS ANGELES--(BUSINESS WIRE)--SpineX Inc. has closed recruitment for its clinical trial of its proprietary SCONE™ device. The clinical trial—Spinal COrd NeuromodulaTor by SpIneX and ScoNE to Treat NeurogeniC BladdEr - SCONE “CONTINENCE” Clinical Study— began in May 2022. SCONE is an innovative device that treats urinary incontinence allowing people living with neurogenic bladder due to spinal cord injury, multiple sclerosis, or stroke to live life on their own terms. SpineX scientists and resea...

SpineX Announces Successful in-Human Results to Treat Adults with Cerebral Palsy

LOS ANGELES--(BUSINESS WIRE)--SpineX Inc. today announced groundbreaking results in its first in-human study treating an adult with Cerebral Palsy (CP). The study, published in the esteemed medical journal BioElectronic Medicine, demonstrates significant functional improvements in an adult with CP after treatment with the company’s proprietary non-surgical SCiP™ therapy. Led by Drs. Rahul Sachdeva, PhD and Kristin Girshin, PT, DPT, this study affirms how after just eight weeks of SCiP therapy t...
Back to Newsroom